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Abstract 
Background 
The surface of the human eye is covered by corneal epithelial cells (CECs) which regenerate 
from a small population of limbal epithelial stem cells (LESCs). Cell therapy with LESCs is a 
non-penetrating treatment for preventing blindness due to LESC deficiency or dysfunction. 
Our aim was to identify new putative molecular markers and upstream regulators in the 
LESCs and associated molecular pathways. 
Results 
Genome-wide microarray transcriptional profiling was used to compare LESCs to 
differentiated human CECs. Ingenuity-based pathway analysis was applied to identify 
upstream regulators and pathways specific to LESCs. ELISA and flow cytometry were used 
to measure secreted and surface expressed proteins, respectively. More than 2 fold increase 
and decrease in expression could be found in 1830 genes between the two cell types. A 
number of molecules functioning in cellular movement (381), proliferation (567), 
development (552), death and survival (520), and cell-to-cell signaling (290) were detected 
having top biological functions in LESCs and several of these were confirmed by flow 
cytometric surface protein analysis. Custom-selected gene groups related to stemness, 
differentiation, cell adhesion, cytokines and growth factors as well as angiogenesis could be 
analyzed. The results show that LESCs play a key role not only in epithelial differentiation 
and tissue repair, but also in controlling angiogenesis and extracellular matrix integrity. Some 
pro-inflammatory cytokines were found to be important in stemness-, differentiation- and 
angiogenesis-related biological functions: IL-6 and IL-8 participated in most of these 
biological pathways as validated by their secretion from LESC cultures. 
Conclusions 
The gene and molecular pathways may provide a more specific understanding of the 
signaling molecules associated with LESCs, therefore, help better identify and use these cells 
in the treatment of ocular surface diseases. 
Keywords 
Limbal epithelial stem cells, Corneal epithelial cells, Gene array, Upstream regulators, 
Cytokines, Cell adhesion, Angiogenesis, IL-6, IL-8 
Background 
The cornea serves mainly a protective and refractive function, being found on the outermost 
surface of the eye. It is a highly transparent and strong tissue, separated from the surrounding 
conjunctiva by a transitional zone - the limbus. During eye development, the cornea is the last 
part of the eye to be formed. It consists of a stratified epithelium at the surface, stroma in the 
middle - populated by keratocytes and fibroblast-like cells, and an inner layer of endothelial 
cells, each separated by a Bowman’s and Descemet’s membrane, respectively. 
The human central corneal epithelial cells (CECs) are derived and replaced continuously 
from the limbal epithelial stem cells (LESC). The later can undergo asymmetric division and 
give rise to transient amplifying cells (TACs), which can then differentiate into mature CECs 
that lose their ability to proliferate [1,2]. Animal studies have shown that CECs arise from 
approximately 100 progenitor cells, which means the frequency of LESCs is extremely low 
[3]. In humans, the LESCs have been found in the limbal epithelial crypts - special niches at 
the peripheral edge of the cornea [4-6]. Only six such crypts have been identified in the 
limbus, further strengthened by findings from animals [4]. The crypts provide a concentrated 
and safe place for harboring LESCs, and also, a rich vascular supply with growth factors and 
metabolites for their sustained persistence [1,7-10]. LESCs play a key role not only in 
epithelial differentiation, but also in wound healing, tissue regeneration and maintenance of a 
balanced immunological state in the cornea [11]. 
Injuries - traumatic, chemical or iatrogenic, or diseases of the LESCs, either inborn or 
acquired, can all lead to partial or total LESC deficiency (LESCD) or corneal 
neovascularization accompanied by inflammation. Full penetrating keratoplasty is not 
anymore the mainstay of treatment for LESCDs, while autologous limbal graft 
transplantation from a healthy donor eye, if available, does not provide a guarantee for the 
functionality of the graft itself. Isolation and ex vivo expansion of autologous or homologous 
LESCs in human-like conditions has only been described in detail in the last couple of years 
[12]. We recently published a method for cultivating and characterizing LESCs grown on 
lens capsule in a medium containing human serum as the only growth supplement [13]. The 
benefit of our method is not only the use of animal material-free culturing conditions, but 
also, the ability to investigate the phenotype and the genotype of the outgrowing cells, which 
can further help identify new putative LESC markers. 
In the present study, we compare the gene expression patterns of ex vivo cultured human 
LESCs to differentiated CECs with a main focus on markers for stemness and proliferation, 
epithelial differentiation, tissue development and growth, immunological and angiogenic 
factors. In addition, we propose a way to identify and possibly concentrate these stem cells 
found at low density from the heterogeneous cell populations found in the cornea for future 
use in clinical transplantation. 
Methods 
Ethics statement 
All tissue collection complied with the guidelines of the Helsinki Declaration and was 
approved by the Regional Ethical Committee (DEOEC RKEB/IKEB 3094/2010). Limbal 
tissue collection was done within 12 hours of biologic death from cadavers only and Hungary 
follows the EU Member States’ Directive 2004/23/EC on presumed consent practice for 
tissue collection [14]. 
Isolation and cultivation of LESCs and CECs 
In brief, after a thorough eye wash with 5% povidone iodine (Betadine; Egis Pharmaceuticals 
PLC, Budapest Hungary), the conjunctiva was incised and separated from the limbal 
junction; consequently, a 2 × 1 mm rectangular-shaped limbal graft was dissected away and 
towards the cornea, respectively, at the 12 o’clock position. The depth of the graft was kept 
superficial or within the epithelial layer; multiple grafts were collected from a single eye and 
tested for growth potential. The graft dissection was performed using a lamellar knife placed 
tangential to the surface being cut. LESCs were cultured in a high-glucose Dulbecco-
modified Eagle’s medium (DMEM-HG, Sigma-Aldrich, Budapest, Hungary) supplemented 
with 20% v/v human AB serum, 200 mM/mL L-glutamine, 10,000 U/mL penicillin- 10 
mg/mL streptomycin (all from Sigma-Aldrich) at 37°C, 5% CO2 in 1.91 cm2 tissue culture 
plates, while the medium was changed every alternate day. The growth of the cells was 
monitored under phase contrast microscope regularly. Only grafts which had cell outgrowth 
within 24 hours were processed further to decrease the chance of fibroblast contamination 
and maintained in culture up to 14 days when they reached 95-100% confluence. 
Differentiated CECs were scraped from the central part of the cornea of cadavers and were 
used as a positive control. To avoid contamination of one or the other cell type during 
isolation, different donors were used for each isolation carried out. 
Microarray and data analysis 
Affymetrix GeneChip Human Gene 1.0 ST Arrays (Affymetrix, Santa Clara, CA, USA) were 
used for the microarray analysis. The array contained more than 28,000 gene transcripts. For 
the whole genome gene expression analysis 150 ng of total RNA was subjected to Ambion 
WT Expression Kit (Ambion, Life Technologies, Carlsbad, CA, USA ) and GeneChip WT 
Terminal Labeling Kit (Affymetrix) according to the manufacturers’ protocols. After 
washing, the arrays were stained using the FS-450 fluidics station (Affymetrix) and signal 
intensities were detected by Hewlett Packard Gene Array Scanner 3000 7G (Hewlett Packard, 
Palo Alto, CA, USA). The scanned images were processed using GeneChip Command 
Console Software (AGCC) (Affymetrix) and the CEL files were imported into Partek 
Genomics Suite software (Partek, Inc. MO, USA). Robust microarray analysis (RMA) was 
applied for normalization. Gene transcripts with a maximal signal values less than 32 across 
all arrays were removed to filter for low and non-expressed genes, reducing the number of 
gene transcripts to 23190. Differentially expressed genes between groups were identified 
using one-way ANOVA analysis in Partek Genomics Suite Software. Clustering analysis was 
made using the same name module in a Partek Genomics Suite Software. 
Pathway analysis 
To identify the relationships between selected genes, the Ingenuity Pathway Analysis (IPA, 
Ingenuity Systems, Redwood City, CA) was used. Excel datasheets containing gene IDs with 
the assigned gene expression values were uploaded into the program. The Ingenuity 
Pathways Knowledge Base (IPKB) provided all known functions and interactions which were 
published in the literature. ANOVA was used to calculate a p-value to determine the 
probability that each biologic function or canonical pathway assigned to the data set was due 
to chance alone. For the representation of the relationships between the genes, the ‘Pathway 
Designer’ tool of the IPA software was used. 
Measurement of cytokine concentrations by ELISA 
LESCs growing out of the limbal grafts were trypsinized (0.025% trypsin-EDTA (PAA, 
Pasching, Austria, 5 minutes, 37°C) and seeded onto 24-well plates at a 5x104 cell/mL 
density. Cells were cultured for 9 to 13 days. At the end of the culturing period, the 
supernatants were harvested and kept at −20°C until further measurement. BD OptEIA 
ELISA (BD Pharmingen, San Diego, CA, USA) assay kits were used following the supplier’s 
instruction to measure the concentration of secreted IL-6 and IL-8 cytokines. Each 
experiment was performed at least three times and each sample was tested in triplicates. 
Statistically significant differences were determined by paired student’s t test. 
Transmission electron microscopy 
Human corneal tissue procurement and use were conducted in accordance with local 
regulations and approved by the Research Ethics Committee of King Saud University. Unless 
specified otherwise, reagents were obtained from TAAB Laboratories Equipment Ltd 
(Aldermaston, UK). Pieces of LESCs grown on lens capsules were fixed in freshly prepared 
4% paraformaldehyde in 0.1 M phosphate for 2 h at 4°C. Tissues were processed at low 
temperatures and were embedded in LR White resin (Sigma-Aldrich) at −20°C for 48 h under 
ultraviolet light. Ultrathin sections were collected on 200 mesh formvar-coated carbon nickel 
grids and examined in a Jeol 1400 transmission electron microscope (Jeol Ltd, Tokyo, Japan). 
Surface protein level analysis by flow cytometry 
Fluorescein isothiocyanate (FITC), phycoerythrin (PE) and allophycocyanin (APC) 
conjugated antibodies were used for multicolour flow cytometric analysis to measure the 
selected surface protein expression on isolated LESCs and differentiated CECs. Antibodies 
against CD29/Integrin β1, CD44/HCAM, CD45, CD54/ICAM1, CD73, CD90/Thy-1, 
CD117/c-kit and CD146/MCAM markers were used in a concentration specified by the 
manufacturer’s protocol (all antibodies were obtained from Biolegend, San Diego, CA, 
USA). All samples were labeled for 30 minutes on ice, then measured by FACSCalibur flow 
cytometer (BD Biosciences Immunocytometry Systems, San Jose, CA, USA) and the data 
were analyzed using FlowJo (TreeStar, Ashland, OR, USA), software. The results were 
expressed as means of positive cells (%) ± SD. Statistically significant difference between the 
two groups (LESC vs. CECS) was determined with paired student-t test and a value of p < 
0.05 was considered significant. 
Results 
Gene array and IPA analysis 
A microarray based transcriptional profiling was used to compare LESCs to differentiated 
CECs. The intensity profiles of the log2 transformed signal values of the 28869 transcripts 
were obtained, out of which 955 and 875 transcripts had a more than 2 fold change (FC) 
increase and decrease in expression between the two cell types, respectively (n = 3, p < 0.01). 
Table 1 summarizes the most affected signaling pathways identified by the IPA software 
based on the significant expression of genes in the LESCs. The top canonical pathways 
included genes involved in hepatic fibrosis, angiogenesis inhibition by thrombospondin 1 
(TSP-1), retinoic acid receptor (RAR) activation, antigen presentation and axonal guidance 
signaling. Some of the signaling pathways were also related to diseases or toxicological 
pathways such as induction of reactive metabolites, renal ischemia and renal proliferation. 
IPA could determine the biological functions and diseases from the significantly changed 
expression levels of groups of genes: 733 molecules were found to be involved in cancer 
development, 567 in cellular growth and proliferation, 552 in cellular development, 520 in 
cell death and survival and 402 in gastrointestinal diseases. Only a small number of 
molecules related to visual system development and function (98), and 5 involved in 
increased levels of albumin could be detected. (for more details see Table 2). 
Table 1 The most significantly affected canonical pathways found in LESCs 
 Ingenuity canonical pathways -Log(B-H-P-value) Ratio 
Top canonical pathways Hepatic fibrosis/hepatic stellate cell activation 8.36E-05 32/142 (0.225) 
Inhibition of angiogenesis by TSP1 2.22E-04 12/34 (0.353) 
RAR activation 5.01E-04 35/179 (0.196) 
Antigen presentation pathway 1.25E-03 11/40 (0.275) 
Axonal guidance signaling 1.31E-03 65/432 (0.15) 
Top tox (toxicological) pathways Hepatic fibrosis 4.25E-06 27/93 (0.29) 
Glutathione depletion - cyp induction and reactive metabolites 6.6E-05 7/12 (0.583) 
Liver proliferation 1.5E-04 39/189 (0.206) 
Persistent renal ischemia-Reperfusion injury (mouse) 4.41E-04 10/30 (0.333) 
Increases renal proliferation 4.54E-04 24/101 (0.238) 
IPA software was used to calculate the canonical pathways from the gene expression profile of LESCs grown on lens capsule. 
Table 2 Top biological and toxicological functions 
Function Name p value Molecules 
Diseases and disorders Cancer 5.96E-27 - 1.23E-03 733 
Reproductive system disease 1.61E-16 - 1.19E-03 344 
Dermatological diseases and conditions 3.42E-16 - 1.15E-03 282 
Gastrointestinal disease 4.31E-13 - 8.26E-04 402 
Endocrine system disorders 2.65E-10 - 7.46E-04 257 
Molecular and cellular functions Cellular movement 5.90E-18 - 1.43E-03 381 
Cellular growth and proliferation 1.31E-10 - 1.12E-03 567 
Cellular development 3.26E-09 - 1.07E-03 552 
Cell-to-cell signaling and interaction 8.23E-09 - 1.48E-03 290 
Cell death and survival 1.04E-08 - 1.48E-03 520 
Physiological system development and function Cardiovascular system development and function 9.52E-10 - 1.23E-03 271 
Tumor morphology 6.48E-09 - 9.47E-04 140 
Organismal development 9.59E-09 - 1.48E-03 371 
Visual system development and function 1.34E-07 - 1.48E-03 98 
Tissue development 2.59E-07 - 1.48E-03 350 
Clinical chemistry and hematology Decreased levels of albumin 1.63E-03 - 3.94E-01 6 
Increased levels of alkaline phosphatase 2.79E-03 - 1.18E-01 16 
Increased levels of creatinine 8.01E-03 - 8.01E-03 8 
Increased levels of potassium 1.48E-02 - 5.41E-01 7 
Increased levels of albumin 1.09E-01 - 2.21E-01 5 
Cardiotoxicity Cardiac stenosis 6.92E-04 - 3.13E-01 15 
Congenital heart anomaly 3.64E-03 - 5.28E-01 23 
Cardiac arteriopathy 4.20E-03 - 6.33E-01 42 
Pulmonary hypertension 5.95E-03 - 1.18E-01 11 
Cardiac hypertrophy 8.04E-03 - 1.00E00 51 
Hepatotoxicity Liver proliferation 2.37E-04 - 3.13E-01 39 
Liver cholestasis 6.93E-04 - 5.84E-01 22 
Liver cirrhosis 7.33E-04 - 2.21E-01 31 
Liver damage 8.26E-04 - 2.21E-01 33 
Liver hyperplasia/hyperproliferation 8.39E-03 - 5.03E-01 80 
Nephrotoxicity Renal proliferation 6.16E-06 - 2.21E-01 38 
Renal damage 7.17E-04 - 5.03E-01 37 
Renal tubule injury 7.17E-04 - 2.21E-01 24 
Renal necrosis/cell death 1.84E-03 - 1.00E00 52 
Renal inflammation 8.70E-03 - 1.00E00 34 
The most affected pathways related to known biological and toxicological functions in LESCs as determined by the IPA software. 
Customized gene array data – upstream regulators 
We selected 257 upstream regulators that were expressed significantly and differentially in 
LESCs that were also related to our groups of interest (stemness and proliferation, 
differentiation, cell adhesion, cytokines and growth factors and angiogenesis). Their 
biological functions were extensively related to physiological maintenance of LESCs, while 
the molecules involved in these processes showed significant inter-donor differences. Figure 
1 shows the heatmap and the functional clustering of the 257 upstream regulators selected on 
the basis of their high or low FC or previously documented relation to LESCs. The cluster 
analysis demonstrated a clear distinction between the LESCs and our control CECs. The 
genes that were mostly affected were involved in ion-, nucleotide- or protein binding, protein 
secretion as well as receptor or enzyme activities. Table 3 shows the top 20 up- or down-
regulated genes within these gene groups. 
Figure 1 Heatmap of the differentially expressed genes in LESCs compared to CECs. 
Heatmap of the transcripts and functional clustering of 257 genes expressed significantly 
different in LESCs and CECs, and related to stemness, epithelial differentiation, tissue 
organization and angiogenesis. Red and blue colors indicate high and low expression, 
respectively. The cluster analysis and dendrogram show the difference between the two cell 
types (A). Distribution of the 257 significantly differentially expressed genes by molecule 
type as defined by IPA (B). 
Table 3 Top 20 up- and down-regulated custom selected genes in LESC 
Symbol Entrez gene name Fold 
change 
Activation z-
score 
p-value of 
overlap 
Molecule type 
Fold change up-regulated 
FN1 Fibronectin 1 74.934 2.979 8.37E-05 Enzyme 
CCNA1 Cyclin A1 27.199  3.42E-02 Other 
IL1B Interleukin 1, beta 24.948 4.924 8.09E-15 Cytokine 
INHBA Inhibin, beta A 21.815 1.352 2.27E-04 Growth factor 
SERPINE1 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), 
member 1 
18.854 −0.927 1.40E-02 Other 
GDF15 Growth differentiation factor 15 16.924 1.999 2.63E-02 Growth factor 
PTHLH Parathyroid hormone-like hormone 16.2 1.972 8.72E-03 Other 
OSMR Oncostatin M receptor 15.366 1.982 1.83E-02 Transmembrane receptor 
CXCL10 Chemokine (C-X-C motif) ligand 10 15.171 0.911 2.31E-02 Cytokine 
MMP9 Matrix metallopeptidase 9 (gelatinase B, 92 kDa type IV collagenase) 14.243 0.689 1.72E-02 Peptidase 
IL1R1 interleukin 1 receptor, type I 13.972 2.603 5.76E-03 Transmembrane receptor 
MMP1 Matrix metallopeptidase 1 (interstitial collagenase) 13.875 1.188 4.01E-03 Peptidase 
ICAM1 Intercellular adhesion molecule 1 13.681 2.961 1.36E-03 Transmembrane receptor 
ITGA5 Integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 13.455 2.411 1.46E-02 Other 
SH3KBP1 SH3-domain kinase binding protein 1 12.752  4.98E-02 Other 
AKT3 V-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) 11.843  4.76E-02 Kinase 
LOXL2 Lysyl oxidase-like 2 11.734 1.992 1.88E-03 Enzyme 
CEACAM5 Carcinoembryonic antigen-related cell adhesion molecule 5 10.588  1.23E-02 Other 
SLPI secretory leukocyte peptidase inhibitor 8.53 −2.433 1.06E-02 Other 
PDZK1IP1 PDZK1 interacting protein 1 8.485  1.23E-02 Other 
Fold change down-regulated 
CRTAC1 - cartilage acidic protein 1 −72.277    
LPA Lipoprotein, Lp(a) −11,623  4.98E-02 Other 
ETV1 Ets variant gene 1 −7,444 1.969 1.83E-02 Transcription regulator 
EDNRB Endothelin receptor type B −7,25  3.38E-02 G-protein coupled receptor 
BMP7 Bone morphogenetic protein 7 −6,436 0.733 1.17E-04 Growth factor 
NREP Neuronal regeneration related protein −5,823 −0.248 3.81E-03 Other 
CFTR Cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family 
C, member 7) 
−5,766 −1.993 1.49E-01 Ion channel 
DCN Decorin −5,066 0.172 6.04E-07 Other 
RORA RAR-related orphan receptor alpha −4,781 −0.439 2.61E-03 Ligand-dependent nuclear 
receptor 
LEF1 Lymphoid enhancer binding factor 1 −4,441 −0.306 2.01E-02 Transcription regulator 
BDKRB1 Bradykinin receptor B1 −4,1 −2.000 6.89E-04 G-protein coupled receptor 
GJA1 Gap junction protein, alpha 1 −3,94 −1.480 5.54E-04 Transporter 
FAM3B Family with sequence similarity 3, member B −3,9  3.20E-08 Cytokine 
P2RX7 Purinergic receptor P2X, ligand-gated ion channel, 7 −3,885  1.15E-02 Ion channel 
KAT2B K(lysine) acetyltransferase 2B −3,829 1.963 8.27E-02 Transcription regulator 
ODC1 Ornithine decarboxylase, structural 1 −3,63  4.98E-02 Enzyme 
EPHX2 Epoxide hydrolase 2, cytoplasm −3,469  3.42E-02 Enzyme 
MAT1A Methionine adenosyltransferase I, alpha −3,386 −0.215 1.82E-02 Enzyme 
CTSL2 Cathepsin L2 −3,385  4.98E-02 Peptidase 
DUSP1 Dual specificity phosphatase 1 −3,358 −1.881 6.12E-02 Phosphatase 
NOV Nephroblastoma overexpressed −3,149 0.555 1.94E-02 Growth factor 
The top 20 up and down regulated genes in LESCs as determined by the IPA software. 
Customized gene networks – upstream regulators 
Stemness and proliferation 
As seen in Figure 2, out of the 257 upstream regulators, 122 were related to stemness and, in 
particular, mesenchymal stem cells (MSCs). The expression pattern also demonstrated a clear 
difference between the LESCs and the CECs (Figure 2A). These genes coded for 
transcription factors, surface molecules, cytokines and growth factors, all playing a key role 
in the maintenance of multipotency, proliferation capacity of hematopoietic and/or MSCs 
(Figure 2B). Up- and down- regulation was found in 66 and 56 genes, respectively, and 
within the custom selected gene cluster, the 10 highest upstream regulators were: CCNA1 
(27.199 fold), IL1B (24.948), GDF15 (16.924), ICAM1 (13.681), TGFB (16.745) SOX9 
(4.859 fold) VIM (4.368), NT5E (4.009) TGFBR2 (3.772) and BMP6 (3.494), while the 10 
most down-regulated were: BMP7 (−6.436 fold), LEF1 (−4.441), GJA1 (−3.94), KAT2B 
(−3.829), KLF4 (−3.041), EGF (−2.563) FOXN1 (−2.11), SOX6 (−1.984), GDF9 (−1.865) 
and HSPA9 (−1.838). The expression of these selected genes strengthen our previous findings 
that the ex vivo cultured LESCs show great similarity to MSCs regarding their surface marker 
profile and the extracellular matrix (ECM) production ability [13]. The present comparison is 
rather focused on the differences between LESCs and differentiated CECs in their 
transcriptional factor patterns, making the LESCs more progenitor-like, yet with a limited 
multipotency potential as compared to other stem cells, including bone marrow-derived 
MSCs (bmMSCs). As expected, our data show that LESCs have a higher proliferation 
potential and stemness-related gene expression than differentiated CECs. The SRY related 
HMG-box family members SOX9 and SOX6, both involved in chondrogenesis and 
proliferation, were down-regulated in the LESCs. Flow cytometric surface protein level 
analysis found a significantly higher number of positive cells for ICAM1 in CECs (56.19 ± 
12.46%) than in LESCs (4.37 ± 7.63%) (p = 0.0001) (Additional file 1: Figure S1). No 
difference could be found in the well-known MSC surface markers, such as CD90 (8.75 ± 
19.56% in LESCs and 1.77 ± 3.54% in CECs, respectively (p = 0.4748)) and CD73 (89.86 ± 
6.15% in LECSs and 76.93 ± 17.43% in CECs, respectively, (p = 0.2374); data shown are 
Mean ± SD), while more cells expressed the stem cell factor receptor CD117/c-kit in the 
LESCs (19.87 ± 24.92%) compared to CECs (0 ± 0%) at a protein level, however, this 
difference was not statistically significant (p = 0.1491) due to a high inter-donor variance 
(Additional file 1: Figure S1.). 
Figure 2 Upstream regulators as determinants for stemness. Selected upstream regulator 
genes which are involved in the maintenance of stemness, cell cycle and multipotency-related 
transcription factors (A), and growth factors, cytokines and corresponding receptors (B). The 
gene characteristics of MSCs are highlighted as well. 
Differentiation 
Our previous phenotype analysis of LESCs showed the heterogeneity of this population [13], 
so we analyzed 42 genes related to terminal and epithelial differentiation. The heatmap of 
these transcripts with the clustering of the expressed genes show a clear segregation of the 
LESCs from the differentiated CECs (Figure 3A). Among them, growth factors, cytokines, 
adhesion molecules, transcription regulators and enzymes can be found (Figure 3B). 
Transcriptional regulators such as FOXG1 (−1.165), FOXD3 (−1.1), MYOD1 and OSGIN1 
(−1.109) were all down-regulated in contrast to the FOXA1 and PMEL up-regulation (Figure 
3C). The pericellular matrix proteoglycan decorin coding gene DCN (−5.066) was found to 
be down-regulated in LESCs. Within the collection of cytokines and growth factors which 
play a role in epithelial differentiation, BMP7 (−6.436 fold), FGF1 (−2.96), FGF7 (−1.473), 
IL18 (−1.152) and IGF2 (−1.126) were down-, while IL1B (24.948), INHBA (21.815), IL1A 
(7.853), TGFB1 (6.745), EREG (3.836), BMP6 (3.494) and DKK1 (2.88) were up-regulated 
(Figure 3D). At a protein level, CD146/MCAM, a key player in MSCs differentiation, was 
found not to be expressed on the surface of CECs (0 ± 0%) compared to LESCs (82.40 ± 
14.60%, p = 0.0002) (Additional file 1: Figure S1). Presence of CK14 on LESCs has been 
described by our group previously [13] 
Figure 3 Expression of terminal differentiation related genes. Expression of transcription 
factors, transmembrane receptors, enzymes and adhesion molecules (A). Subgroups of 
cytokines- and growth factor coding genes involved in epithelial differentiation of stem cells 
(B). Distribution of the selected 42 upstream regulators by molecule type, such as 
transcriptional regulators (C) and growth factors and cytokines (D). 
Cell adhesion 
To further distinct the multipotent LESCs within the heterogeneous population of epithelial 
cells, surface markers including ECM-cell, cell-cell adhesion and cell migration proteins 
were used as putative markers. The upstream regulators of 54 genes coding for molecules 
involved in cell adhesion were analyzed. (Figure 4A, E). The first subgroup contained highly 
expressed transcriptional factors and transmembrane receptors in the LESCs (Figure 4C): 
TGFBI (6.745), AKT3 (11.843), CTGF (6.513), MAP2K (12.088), SPP1 (2.077) and SRC 
(1.931). Six genes including AKT1 (−1.026), NOV (−3.149), ROCK2 (−1.076), PRKCA 
(−1.154), HRAS (−1.5) and PRKCB (−1.583) were down-regulated. The next subgroup 
(Figure 4D), included integrins, cell adhesion molecules (CAMs), proteolytic enzymes and 
matrix metalloproteases (MMPs) – all involved in the ECM breakdown and tissue healing 
and remodeling; the most up-regulated genes in this cluster were MMP1 (13.875), MMP14 
(1.836) and MMP9 (14.243), while MMP3 was down-regulated (−1.105). The laminins, 
which are important proteins in the basal membrane and their coding genes such as LAMA1 
(1.428), LAMA3 (3.289) and LAMC1 (1.724) were all up-regulated in the LESCs. CAMs and 
tight junctions which are very important in cell-cell adhesion and tissue organization, such as 
ICAM-1 (13.681), CAV1 (1.608) and CLDN7 (3.056) were up-, while GJA1 (−3.94) was 
down- regulated. In particular, CDH1 (1.536), important in desmosomal junction formation 
and stratified epithelium transformation was up-regulated, and the desmosome formation 
between the LESCs grown on lens capsule could be demonstrated using transmission electron 
microscopy (Figure 4B). Altogether, the expression of 11 integrin-coding genes was different 
between the LESCs and the differentiated CECs - 8 out of them were up-, while 3 were 
down- regulated. Surface protein level analysis found no difference between LESCs and 
CECs in the expression of CD29/Integrin β1 (97.01 ± 1.87% and 78.28 ± 15.84%, 
respectively), and CD44/HCAM (16.55 ± 23.21% and 19.83 ± 21.55%, respectively) 
expression. The percentage of CD47 positive cells, which plays a role in cell viability and 
immunoregulation, was significantly higher in LESCs (98.98 ± 0.57%) compared to CECs 
(25.9 ± 27.44%) (p = 0.0039), showing higher viability and inhibition of phagocytosis in the 
LESCs (Additional file 1: Figure S1). 
Figure 4 Differential changes in selected genes related to cell-cell junction, cell-to-cell 
and cell-to-extracellular matrix (ECM) adhesion. Collection of significantly different 
expressions of transcription factors, kinases and transmembrane receptors related to cell-cell 
connection and adhesion (A). CAMs, integrins and ECM receptors determine the tissue origin 
of LESCs (C and D). Molecule types of the selected 54 upstream regulator in the two groups 
of cells (E). TEM pictures about LESCs on lens capsule shows the cell-cell junctions 
between the cells (B) (LC = Lens capsule, A = Attachment between LC and cells; C1, ,, C2 
and C3 - three cell-layer, L = translucent space, D = Desmosomes 
Cytokines and growth factors 
Cytokines and growth factors have an important function in cell-cell communication and can 
affect cell function, differentiation and immunogenicity (Figure 5A). IL1B was the most up-
regulated gene (24.948 fold), followed by CXCL10 (15.171), IL1A (7.853), IL8 (5.849), 
EDN1 (5.504), IFNE (4.601), IL6 (2.57), SPP1 (2.077) and CCL5 (1.973). Although most of 
the up-regulated genes were related to pro-inflammatory cytokines, some members with 
similar pro-inflammatory properties, but from other cytokine families, were down-regulated: 
IL17 (−1.129), the IL-1 superfamily members IL18 (−1.152) and IL36RN (−1.059). Human 
EDA (−1.113) which belongs to the TNF family was within the most down-regulated genes, 
while the top down-regulated gene was FAM3B (−3.900) (Figure 5B). Next, we filtered out 
the entire dataset for growth factors, all being important for maintaining multipotency and 
differentiation of progenitor or stem cells (Figure 5C). The most up-regulated genes were 
members of the TGF beta (TGFβ) superfamily: INHBA (21.815 fold), GDF15 (16.924), 
TGFB1 (6.745) and BMP6 (3.494). Epiregulin and amphiregulin, members of the epidermal 
growth factor (EGF) family, were the top up-regulated genes: EREG (3.836) and AREG 
(4.047), as well as connective tissue growth factor CTGF (6.513). The down-regulated genes 
included other TGFβ superfamily members: BMP7 (−6.436) and GDF9 (−1.865). Acidic 
fibroblast growth factor, FGF1 (−2.96) and FGF7 (−1.473) were also down-regulated, as 
well as NOV-like CTGF- member of the CCN protein family: nephroblastoma 
overexpressed/NOV (−3.149). Similarly, EGF gene expression responsible for regulation of 
cell division and proliferation was down-regulated −2.563 fold. 
Figure 5 Differences in the expression of the cytokines and growth factors coding genes. 
Heatmap of the transcripts of cytokines- and growth factors- coded genes in LESCs and 
CECs (A). Selection of significantly and differentially expressed genes of cytokines (B); and 
differentiation and growth factors (C). In comparison to CECs, the LESCs expressed 37 
cytokine and 40 growth factor coding genes in a significantly different manner. 
Angiogenesis 
48 molecules were detected in the dataset which may have a role in pathological angiogenesis 
in the cornea (Figure 6A). This set contained transcription factors, enzymes and cytokines 
including angiogenic growth factors as well (Figure 6B). The fibronectin gene (FN1), which 
is important in new vessel sprout formation, had the highest up-regulation (74.934), followed 
by SERPINE1 (18.854) and MMP9 (14.243). The coagulation factor III (thromboplastin) 
gene F3 (7.054) was also highly expressed in the LESCs. The most down-regulated genes 
were PLG (−2.521), TIMP1 (−1.658), FOXO4 (−1.213), TGFBR1 (−1.179) (Figure 6C). 
Certain cytokines and growth factors which are also important in angiogenesis (Figure 6D) 
were up-regulated in the LESCs: ILB1 (24.948), C-X-C motif chemokine 10, CXCL10 
(15.171), TGFB1 (6.745) and VEGFA (2.742). In addition, IL-6 and IL-8, two very potent 
angiogenic cytokines, were up-regulated in these cells: IL-6 (2.57) and IL-8 (5.849), similar 
to EDN1 (5.504), EREG (3.836) and BMP2 (2.686) up-regulation within this cluster. Only 
four of the angiogenic cytokines were down-regulated in the LESCs: acidic FGF - FGF1 
(−2.96), IL17F (−1.129), TGFB2 (−1.106) and KITLG (−1.015). 
Figure 6 Significantly expressed angiogenesis-related genes in LESCs. Angiogenesis is a 
complex process mediated by MMPs, proteolytic enzymes and ECM proteins (A). Cytokines 
and growth factors are important players of angiogenesis with endothelial cell activation and 
EPC/stem cell differentiation (B). Most of the angiogenic molecules belong to these molecule 
types (C and D). 
Discussion 
Absence or removal of the LESC layer in animals can cause defective corneal 
epithelialization, indicating the essential importance of these cells in corneal surface biology 
and regeneration [15,16]. In humans, besides injuries and diseases, dysfunction or LESC loss 
can lead to LESCD; other causes, such as genetic diseases can cause abnormal development 
of the anterior segment and the limbus, while Steven Johnson syndrome, chronic limbitis or 
ocular pemphigoid are inflammatory processes which can lead to LESCD, similar to 
cytotherapy, radiation or surgery in the limbal region [9,17]. Altogether, a plethora of causes 
can lead to decreased transparency of the cornea, inflammation and corneal 
neovascularization (key features of LESCD), resulting in a serious and painful disease with 
subsequent loss of vision [18]. The inflammatory processes and the angiogenesis very likely 
change the environment, so that the small niche of stem cells becomes non-functional 
[6,10,19]. Therefore, the treatment of LESCD with ex vivo cultured and functional LESCs is 
becoming widely accepted today [20]. Many other types of cells, including embryonic stem 
cells, bone-marrow and Wharton jelly-derived stem cells have been attempted for LESCD 
treatment in animal models with relatively good outcomes [17,21]. Most cell-based therapies 
in the clinical practice, however, use limbal epithelial cells cultured on 3 T3 mouse feeder 
fibroblast supplemented with fetal calf serum [22]. The risk of murine (animal) viral 
transmission during such procedures is not yet known [23,24]. Although the limbal epithelial 
cells cultivated on mouse feeder cells can replace the wounded epithelial cells, the 
mechanism how they make the local tissue more suitable for its own stem cells to recover 
their stemness and differentiation potential has been unknown [17]. This seemingly “gold 
standard” cell therapy method would not be able to compete with human animal material-free 
product that would be ideal for clinical use. Furthermore, the overall success rate of the above 
therapies has been reported to be 76% [24], although, the right quantity of cells needed for 
recovery has not yet been reported. In stem cells based therapies, the purity of the product 
(the percentage of stem cells within the cell culture) is crucial for the outcome [24-26]. 
LESCs lose their multipotency during epithelial expansion and differentiation [27], therefore, 
it is important to distinguish between LESCs, TAMs and CECs within the cell culture used 
for therapy. In our cell cultures, the SRY related HMG-box family member SOX9 was up-
regulated, while SOX6 expression was down-regulated, indicating no chondrogenic 
differentiation but high proliferative capacity of the LESCs. Furthermore, S100A4 and A9 
proteins have been found to be potent markers of limbal epithelial crypt cells [28] - in our 
LESCs,- the S100A4 was down-regulated indicating they are not crypt cells. Others have 
reported that CXCL12, COL2A, ISL1, FOXA2, NCAM1, ACAN, GJB1 and MSX1 can be used 
as putative markers to identify LESCs [29]. We could not confirm a difference in these genes 
between the LESCs and the differentiated CECs, with the exception of FOXA1 which was 
up-regulated and GJA1 down-regulated (also known as negative marker for LESCs [30]). 
Similarly, Wnt2, Wnt6, Wnt11 and Wnt16b have been reported to be typically expressed in 
the limbal region and to be important for the LESCs proliferation [31]. We could confirm that 
WNT1 and WNT5A expression was up-, while WNT3A was down- regulated in our LESCs, 
along the wider lines of the results mentioned above. Surface protein level analysis found 
higher positivity for CD146/MCAM, CD47 and CD117/c-kit in LESCs compared to CECs, 
showing a pattern typical for stem cells and higher multipotency in the earlier cell type 
(Additional file 1: Figure S1). This phenotype analysis further proved simply using classical 
MSC markers, such as CD90/Thy-1 and CD73, it is not possible to differentiate between the 
two cell types. 
LESCs play a key role in limbal tissue healing and remodeling, a process which usually starts 
with ECM breakdown [32,33]. The latter is mediated by MMPs, which were up-regulated in 
the LESCs and their pattern implicates a preferred degradation of collagens to rebuild the 
ECM [32]. Laminins and vitronectin are typically found in the limbal basal membrane 
[34,35] and their genes were up-regulated in our LESCs. 
For attachment to new ECM proteins, integrins and CAMs are also essential, the expression 
of which is typical for the tissue of origin. Indeed, the integrin expression is able to define the 
cell phenotype and seems to be useful in classifying MSCs from various tissues besides the 
well-known MSC markers we have reported before [13]. The results of our gene array data 
analysis strengthen the fact that LESCs cultured in medium containing human serum as the 
only growth supplement can keep their integrin and CAM pattern that relates them to their 
limbal tissue phenotype. Surface protein level analysis found same expression levels of 
CD29/Integrinβ1 and CD44/HCAM in the two cell types, while CD54/ICAM1 positivity was 
higher in the CECs (Additional file 1: Figure S1). 
Wound healing can often lead into angiogenesis, which can have a very important and 
controllable pathological role in the limbus [33,36-38]. Fibronectin is an important ECM 
protein in expanding cells as well as angiogenesis, mediating sprouting, de novo vessel 
formation and endothelial progenitor/stem cells differentiation into endothelial cells [39-41]. 
The two highest up-regulated gene products found in our LESCs seem to have an opposite 
effect on the angiogenesis pathway: IL-1β can induce-, while CXCL10 can inhibit the 
formation of new vessels [42-46]. Interestingly, human limbal epithelial progenitor cells have 
been found to express CXCL10 [47] while its absence could decrease the level of IL-6 in 
mice corneas [48]. The expression of TGFB1 is very important in wound healing and in 
inducing VEGF expression, which was also up-regulated in the LESCs, capable of provoking 
angiogenesis in the damaged tissue [49,50]. Endothelin-1 has many direct and indirect 
angiogenic effects upon the endothelial cells and fibroblasts - it provokes the release of the 
pro-angiogenic compounds like VEGF from endothelial cells and stimulates the fibroblasts to 
produce pro-angiogenic proteases [51,52]. Altogether, our results indicate that both pro- and 
anti-angiogenic genes are expressed at the same time or in a balanced way in LESCs, 
maintaining an avascular state in the normal cornea. Loss of this control can be initiated by 
either a decreased production of anti-angiogenic molecules or increased production of pro-
angiogenic and inflammatory factors. Although transplantation of LESCs has been known to 
suppress corneal inflammation and angiogenesis, the molecular mechanism how LESCs 
participate in the processes has not yet been fully understood [9,17,36,53,54]. Limbal niche 
cells have been found to have a differentiating ability towards angiogenic progenitors and 
inhibition of endothelial differentiation of LESCs [53]. 
IL-6 and IL-8 can be secreted by many cell types during inflammation or differentiation. 
These cytokines play a role in inflammation, angiogenesis and MSC differentiation-related 
processes [55]. Their gene expressions were up-regulated in LESCs: IL-6 (2.570) and IL-8 
(5.849). Using the IPA analysis, the IL-6 signaling pathways were further confirmed of being 
present in our LESCs compared to CECs, together with some other well-known pathways 
described below (Additional file 2: Figure S2A). The first such pathway or network affected 
is the IL-1β and TNFα mediated release of IL-6 from activated cells. This signaling is further 
mediated by NFκB and JNK (JUN, C-Fos) transcriptional factors and can lead to IL-6 and IL-
8 release in parallel to collagen type I production (COL1A1), which is the major component 
of connective tissue. The second network affected is the autocrine or IL-6-mediated-IL-6-
secretion through RAF1, MAP2K and ERK1/2. This process needs to be initiated by the IL-6 
receptor (IL6R), however, the JAK-STAT pathway (STAT3) can also induce release of 
angiogenic factors such as VEGF and activation of SOX3. As shown before in our dataset, 
IL1B was highly up-regulated with a 24.948 fold change hand-in-hand with its receptor 
IL1R1 (13.972) and IL1A (7.853). Although a subunit of the receptor for IL-6 coding gene 
was down-regulated - IL6R (−2.640), a member of the type I cytokine receptor family - 
oncostatin M receptor (OSMR), was found to be highly up-regulated (15.366) in the LESCs. 
This receptor can form heterodimers with gp130, which is a signal transducer for IL6R. It can 
also provide an intracellular signal through Janus kinases after ligand binding. In addition, 
many other ligands can be associated with gp130 (and the IL6 receptor as well) such as IL-
11, ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF) and cardiotrophin 1 
(CT-1). Activation of RAS and MAPK signaling can then be connected to the IL-1β mediated 
pathway. In our dataset, SOCS3 was up-regulated (1.397), while SOCS1 was down-regulated 
(−1.120). Four MAPKs were slightly up-regulated in the LESCs: MAP2K1 (2.088), MAPK1 
(1.339), MAPK14 (1.011) and MAPK3 (1.163), while the members of the NFκB pathway 
were down-regulated: NFKB1 (−1.178) and NFKBIA (−1.193). CXCL10 with high amount of 
IL-6 has been shown to induce migration of trophoblasts through activation of the CXCR3 
receptor [56]. Interestingly, CXCL10 was among the highest up-regulated genes (15.171) in 
the LESCs compared to CECs (Additional file 2: Figure S2B). 
The pathways in which IL-8 participates are in general more complex than for other 
cytokines. IL-8 can be produced by any cell possessing toll-like receptors during 
inflammation, and it is one of the most known chemotactic factors for neutrophils and 
activator of immune cells [57]. (Additional file 3: Figure S3A). In addition, IL-8 has been 
described as potent pro-angiogenic cytokine especially in the eye [58,59], although the 
molecular background of such angiogenic processes has not been well described. IL-8 can 
bind to G protein-coupled serpentine receptors such as CXCR1 and CXCR2 and beside 
immunological activation, it can induce rearrangement of cytoskeletal proteins, increase the 
expression of VCAM and ICAM1, and the migration as well as vessel formation of 
endothelial cells and stem cell-like endothelial progenitor cells, in parallel with increase in 
vascular permeability (Additional file 3: Figure S3B). 
Our gene expression data which indicate that IL-6 and IL-8 participate in most of the 
networks or selected pathways analyzed correlate well with the measurements of their 
secreted levels in the supernatants of the cultured LESCs. The level of these cytokines was 
continuously high in the culture supernatants at days 9 (5885.24 ± 685.6 pg/mL) and 13 
(6147.14 ± 530.21 pg/mL) with no significant difference at both time points (p = 0.14) 
(Additional file 4: Figure S4). For comparison, the physiologic level of IL-6 in the tear fluid 
of human subjects is very low (2.4 pg/mL) (data from our group under publication). IL-6 can 
participate in many stem cell-related processes and has been found to be important in 
maintaining the needed niche for LESCs and LESC-epithelial interaction [60]. In bone 
marrow-derived stem cells, IL-6 is needed for immunosuppression, which effect of the 
LESCs has been described with different possible mechanisms [11]. 
Overall, our gene selection and networks are somewhat different from the well-known 
canonical pathways described so far because they were generated de novo and were based on 
our data and the already published networks from literature. It remains to be further 
investigated and confirmed whether these pathways are reflected in the same manner at 
protein level both ex vivo and in situ, giving a possibility of finding a specific phenotype and 
genotype profile for LESCs. These can clearly be beneficial in treating ocular surface 
diseases and discovering innovative therapies aided by the gene array technology. 
Conclusion 
The human eye as an organ possesses great potential for regeneration and cell therapy, in 
particular, its corneal surface which contains LESCs. Identifying molecular markers and 
upstream regulators in the LESCs using genome-wide microarray transcriptional profiling, as 
well as verification of those at protein expression level can provide a better identification and 
more specific understanding of the signaling molecules associated with these cells, therefore, 
better application ocular surface disease treatment. Overall, we found that the human LESCs 
play a crucial role in cellular movement and adhesion, epithelial differentiation and tissue 
repair, as well as angiogenesis and extracellular matrix integrity. 
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Additional file 1: Figure S1. Surface protein level analysis by FACS. Positivity of the 
LECSs and CECs for CD73, CD90/Thy-1, CD117/c-kit, CD146/MCAM stemness markers, 
CD29/Integrin β1, CD44/H-CAM cell adhesion molecules and CD47 cell viability and 
immunoregulatory marker, were determined by flow cytometry. CD45 was used as a negative 
control in these cells (Data shown are Mean ± SD; p < 0.05 *, p < 0.01 **, p < 0.001 ***; N 
= 6). 
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Additional file 2: Figure S2. Networks generated by IPA which are related to the IL-6 
signaling pathway. The colored genes appear in the studied dataset, red colored genes are up-, 
while green colored genes are down-regulated. The grey colored genes did not fit the cut off 
level. (A). 44 upstream regulators of the IL-6 signaling pathway in LESCs when grouped 
upon biological functions of a molecule type (B). 
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Additional file 3: Figure S3. Networks generated by IPA which are related to the IL-8 
mediated signaling pathway. IL-8 plays a key role in innate immunity (A) and as pro-
angiogenic cytokine (B). 
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Additional file 4: Figure S4. Secreted IL-6 and IL-8 levels in LESC cultures. The levels of 
secreted IL-6 and IL-8 as measured by ELISA in the supernatants of long term LESC 
cultures. (N = 21, p values were determined by student’s T test). 
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